Subjects needed for study of medication for rheumatoid arthritis
Researchers in the UC Davis Division of Rheumatology, Allergy and Clinical Immunology are seeking male and female participants for a study that will assess the safety and effectiveness of an investigational medication for rheumatoid arthritis.
To be eligible for the study, subjects must be 18 or older, and have been diagnosed with rheumatoid arthritis for at least six months, and older than 16 when first diagnosed with the disease.
Participation in the study will last up to about five months and be divided into two parts. During part one, which will last about six weeks, participants will receive either a placebo or the medication, called etoricoxib. Placebos are an inactive substance that resemble the investigational medication and are used to ensure that effects observed during the study actually are caused by the medication. There is a one out of 12 chance that a participant will receive the placebo.
Participants will be asked to visit the study site about once every two weeks for a total of four visits, following an initial screening visit. Not all participants will be asked to continue in part two.
Part two will last for an additional six weeks and includes another two visits to the study site. During part two, all participants will receive etoricoxib. Subjects must not have congestive heart failure, uncontrolled high blood pressure, stomach or intestinal ulcers, inflammatory bowel disease, or bleeding disorders. Participants must be willing to take the study medication every morning and agree to discontinue taking certain other rheumatoid arthritis medications, and or remain stable on certain medications for the disease.
The study will provide monetary compensation for participants' time and travel, study-related medical examinations, and laboratory tests.
The principal investigator of the study is Nancy Lane, professor of rheumatology, allergy and clinical immunology. For more information, contact Andrea Picazo at 916-734-3011 or email@example.com.